Download This Paper
Preprints with The Lancet is a collaboration between The Lancet Group of journals and SSRN to facilitate the open sharing of preprints for early engagement, community comment, and collaboration. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early-stage research papers that have not been peer-reviewed. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. The findings should not be used for clinical or public health decision-making or presented without highlighting these facts. For more information, please see the FAQs.
Serum GSDMD as a New Biomarker for Assessing Clinical Progression Of Chronic HBV Infection
39 Pages Posted: 28 Jul 2020
More...Abstract
Background: Distinguishing the natural course of chronic HBV infection (CHB) development is extremely desired. The pore-forming protein Gasdermin D (GSDMD) contributes to the development of HBV infection and might be used to distinguish different phases of CHB. We aim to investigate the serum expression of GSDMD in the natural course of CHB development and to evaluate its diagnostic efficacy.
Methods: Levels of GSDMD were measured with ELISA kits that we developed. We evaluated the ability of serum GSDMD to differentiate clinical stages in 73 CHB patients. Besides, The HepG2-NTCP cells infected by virus from HepAD38-cell and CHB patients’ serum were applied to evaluate the GSDMD expression in vitro.
Findings: The GSDMD elevated gradually with the development of HBV infection (P < 0.05) and the same phenomenon was observed in vitro. A cutoff value as ≤ 3·0 ng/mL identified healthy individuals from liver diseases patients with 96·479 % sensitivity (AUC, 0·954; P < 0.01). When the cutoff value as 3·0-104·5 ng/mL, the AUC and sensitivity of asymptomatic carriers patients were 0·694 and 91·603 %. In CHB patients, with the cutoff value as 104·5-160·0 ng/mL, the AUC and sensitivity were 0·701 and 56·897 %. When the cutoff value as 160-178 ng/mL, the active chronic hepatitis B patients, the AUC and sensitivity were 0·662 and 52·174 %. Additionally, HBV-related cirrhosis patients, GSDMD positive defined as > 178 ng/mL, the sensitivity was 52·174 %.
Interpretation: Serum GSDMD, varied along with the development of HBV-related diseases, making it an early and efficacious serum biomarker for auxiliary definitions of the natural course of CHB.
Funding Statement: This work was supported by the Outstanding Young Talents Plan of the Second Hospital of Chongqing Medical University (Pu Li).
Declaration of Interests: There are no conflicts of interest.
Ethics Approval Statement: The study was carried out based on the principles of the Declaration of Helsinki and was approved by the medical ethics committee of the Second Affiliated Hospital of Chongqing Medical University.
Keywords: Hepatitis B virus; GSDMD; Chronic hepatitis B; Biomarker; Pyroptosis
Suggested Citation: Suggested Citation